Debra J. Poul
Keine laufenden Positionen mehr
Profil
Debra J.
Poul has been Senior Vice President, General Counsel and Secretary of Neose Technologies, Inc. since December 2002.
Previously, she was Vice President, General Counsel and Secretary of Neose Technologies from May 2002 to December 2002 and General Counsel from January 2000 to May 2002 and Of Counsel of Morgan Lewis & Bockius LLP from 1995 to 2000.
From 1978 to 1994, Ms. Poul worked at Dechert LLP, where she served as Counsel from 1989 to 1994.
She received a BA degree from the University of Pennsylvania and a JD from Villanova University.
Ehemalige bekannte Positionen von Debra J. Poul
| Unternehmen | Position | Ende |
|---|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | General Counsel | 08.07.2010 |
Ausbildung von Debra J. Poul
| University of Pennsylvania | Undergraduate Degree |
| Villanova University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
